ProCE Banner Activity

Phase I Trial of Fianlimab (Anti‒LAG-3 mAb) + Cemiplimab (Anti‒PD-1 mAb) in Patients With Advanced Melanoma

Conference Coverage

Fianlimab + cemiplimab demonstrated clinical activity in patients with advanced melanoma who were PD-1/PD-L1 therapy naive, had previous (neo)adjuvant PD-L1 therapy naive or had poor prognostic features.

Released: June 08, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc